Vertex Pharmaceuticals Incorporated
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
Clinical Trials
641
Trial Phases
5 Phases
Drug Approvals
4
Clinical Trials
Distribution across different clinical trial phases (560 trials with phase data)β’ Click on a phase to view related trials
A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
- Conditions
- Primary Membranous Nephropathy
- Interventions
- First Posted Date
- 2025-10-02
- Last Posted Date
- 2025-11-14
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 176
- Registration Number
- NCT07204275
- Locations
- πΊπΈ
Renal Associates, Montgomery, Alabama, United States
πΊπΈClinical Site Partners, LLC - Orlando, Winter Park, Florida, United States
πΊπΈDaVita Clinical Research Columbus, Columbus, Georgia, United States
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-10-27
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT07161037
- Locations
- πΊπΈ
Yale University - Yale Nephrology Clinical Research Clinic, New Haven, Connecticut, United States
πΊπΈAlabama Kidney Research, Alabaster, Alabama, United States
πΊπΈNephrology & Hypertension Associates, PC, Middlebury, Connecticut, United States
Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 148
- Registration Number
- NCT07074327
- Locations
- πΊπΈ
Altasciences - Kansas City, Overland Park, Kansas, United States
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-15
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT07022119
- Locations
- πΊπΈ
ICON Lenexa, Lenexa, Kansas, United States
A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations
- First Posted Date
- 2025-06-08
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 136
- Registration Number
- NCT07010406
- Locations
- πΊπΈ
Celerion - Tempe, Tempe, Arizona, United States
πΊπΈCelerion - Lincoln, Lincoln, Nebraska, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 47
- Next